UY25232A1 - Compuestos terapéuticamente activos basados en el reemplazo bioisostero del catecol por el indazol en inhibidores de pde 4 . - Google Patents
Compuestos terapéuticamente activos basados en el reemplazo bioisostero del catecol por el indazol en inhibidores de pde 4 .Info
- Publication number
- UY25232A1 UY25232A1 UY25232A UY25232A UY25232A1 UY 25232 A1 UY25232 A1 UY 25232A1 UY 25232 A UY25232 A UY 25232A UY 25232 A UY25232 A UY 25232A UY 25232 A1 UY25232 A1 UY 25232A1
- Authority
- UY
- Uruguay
- Prior art keywords
- therapeutically active
- diseases
- indazol
- replacement
- compound
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 abstract 2
- 102100040247 Tumor necrosis factor Human genes 0.000 abstract 2
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 2
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- -1 1-Cyclopentyl-3-ethyl-1H-indazol-6-yl Chemical group 0.000 abstract 1
- BJDNMOQXXVHOJM-UHFFFAOYSA-N 2-(1,3-dithian-2-ylidene)cyclohexane-1-carbonitrile Chemical compound S1C(SCCC1)=C1C(CCCC1)C#N BJDNMOQXXVHOJM-UHFFFAOYSA-N 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 108010044467 Isoenzymes Proteins 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010063837 Reperfusion injury Diseases 0.000 abstract 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000019664 bone resorption disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Otolaryngology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Composiciones terapéuticamente activas útiles para tratamiento o prevención de enfermedades y afecciones que comprenden enfermedades inflamatorias, respiratorias, infecciosas, y otras que incluyen enfermedades de reabsorción ósea y lesiones de reperfusión. También en asma, psoriasis, artritis y otras enfermerdades que implican la producción de TNF.Comprende un compuesto inhibidor de la isoenzima 4 de la fosfodiesterasa (PDE4) y del factor de necrosis tumoral y donde un indazol es componente esencial de la estructura química general de dicho compuesto, y donde el mismo constituye un reemplazo biosostérico de un componente de catecol o de derivado funcional del mismo en un compuesto conocido que tiene la misma dicha actividad terapéutica y los mismos componentes restantes de estructura química global. El agente deseado terapeuticamente activo de formula IA y IB, donde R es H, alquilo, (CH2)n , con n 0,1,2; R1 es H, alquilo, alquenilo; R2a y R2b son H y los sustituyentes (IC,ID,IE,IF) Ejemplo: 1-((1-Ciclopentil-3-etil-1H-indazol-6-il)-4-(1,3ditian-2-ilideno-ciclohexano-carbonitrilo
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6416097P | 1997-11-04 | 1997-11-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY25232A1 true UY25232A1 (es) | 2000-12-29 |
Family
ID=22053970
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY25232A UY25232A1 (es) | 1997-11-04 | 1998-11-04 | Compuestos terapéuticamente activos basados en el reemplazo bioisostero del catecol por el indazol en inhibidores de pde 4 . |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US6716978B2 (es) |
| EP (1) | EP1040100A1 (es) |
| JP (1) | JP2001521925A (es) |
| KR (1) | KR20010031783A (es) |
| CN (1) | CN1281441A (es) |
| AP (1) | AP1122A (es) |
| AR (1) | AR016413A1 (es) |
| AU (1) | AU754184B2 (es) |
| BG (1) | BG104391A (es) |
| BR (1) | BR9813938A (es) |
| CA (1) | CA2309175A1 (es) |
| CZ (1) | CZ20001623A3 (es) |
| DZ (1) | DZ2639A1 (es) |
| EA (1) | EA200000385A1 (es) |
| HN (1) | HN1998000172A (es) |
| HR (1) | HRP20000262A2 (es) |
| HU (1) | HUP0100330A3 (es) |
| ID (1) | ID24942A (es) |
| IL (1) | IL135714A0 (es) |
| IS (1) | IS5452A (es) |
| MA (1) | MA26562A1 (es) |
| NO (1) | NO20002127L (es) |
| NZ (1) | NZ503995A (es) |
| OA (1) | OA11353A (es) |
| PA (1) | PA8462601A1 (es) |
| PE (1) | PE131099A1 (es) |
| PL (1) | PL340799A1 (es) |
| SK (1) | SK6262000A3 (es) |
| TN (1) | TNSN98199A1 (es) |
| TR (1) | TR200001256T2 (es) |
| UY (1) | UY25232A1 (es) |
| WO (1) | WO1999023076A1 (es) |
| YU (1) | YU25400A (es) |
| ZA (1) | ZA9810042B (es) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL126745A (en) * | 1997-11-04 | 2003-09-17 | Pfizer Prod Inc | Methods of preparing 4-cyano-4- (substituted indazole) cyclohexanecarboxylic acids useful as pde4 inhibitors |
| EA200000488A1 (ru) * | 1997-11-04 | 2000-10-30 | Пфайзер Продактс Инк. | Замена катехина на биоизостеру индазола в терапевтически активных соединениях |
| UA71971C2 (en) | 1999-06-04 | 2005-01-17 | Agoron Pharmaceuticals Inc | Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases |
| PE20010306A1 (es) * | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| US7141581B2 (en) | 1999-07-02 | 2006-11-28 | Agouron Pharmaceuticals, Inc. | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use |
| TWI262914B (en) | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| YU54202A (sh) | 2000-01-18 | 2006-01-16 | Agouron Pharmaceuticals Inc. | Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije |
| CA2398446A1 (en) | 2000-04-18 | 2001-10-25 | Agouron Pharmaceuticals, Inc. | Pyrazoles for inhibiting protein kinases |
| US7211594B2 (en) * | 2000-07-31 | 2007-05-01 | Signal Pharmaceuticals, Llc | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith |
| US6897231B2 (en) * | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
| US20040180900A1 (en) * | 2001-05-23 | 2004-09-16 | Masaharu Takigawa | Therapeutic composition for repairing chondropathy |
| HRP20050572A2 (en) * | 2002-11-27 | 2006-08-31 | Altana Pharma Ag | Pde4 and pde3/4 inhibitors for use in the treatment of cachexia |
| US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| JP2005089457A (ja) | 2003-09-03 | 2005-04-07 | Yung Shin Pharmaceutical Industry Co Ltd | 骨成長を促進するまたは骨吸収を阻害するための薬剤組成物 |
| US6984652B2 (en) * | 2003-09-05 | 2006-01-10 | Warner-Lambert Company Llc | Gyrase inhibitors |
| CN104761545A (zh) * | 2004-03-03 | 2015-07-08 | 塔科达有限责任公司 | 新的羟基-6-杂芳基菲啶及其作为pde4抑制剂的用途 |
| CA2584317A1 (en) * | 2004-10-15 | 2006-04-27 | Memory Pharmaceuticals Corporation | Pyrazole derivatives as phosphodiesterase 4 inhibitors |
| US7601847B2 (en) | 2004-10-26 | 2009-10-13 | Wyeth | Preparation and purification of 4-(indazol-3-yl)phenols |
| US20070004777A1 (en) * | 2005-03-23 | 2007-01-04 | Bhagwat Shripad S | Methods for treating or preventing acute myelogenous leukemia |
| EP1928866A1 (en) | 2005-09-05 | 2008-06-11 | Ranbaxy Laboratories Limited | Substituted indazoles as inhibitors of phosphodiesterase type-iv |
| US7915286B2 (en) | 2005-09-16 | 2011-03-29 | Ranbaxy Laboratories Limited | Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors |
| MX2008009022A (es) | 2006-01-13 | 2008-09-24 | Wyeth Corp | 1h-indoles sustituidos por sulfonilo como ligandos para los receptores 5-hidroxitriptamina. |
| PL1981851T3 (pl) | 2006-01-31 | 2012-07-31 | Array Biopharma Inc | Inhibitory kinazy i sposoby ich stosowania |
| DK2124944T3 (da) | 2007-03-14 | 2012-04-23 | Ranbaxy Lab Ltd | Pyrazolo[3,4-b]pyridinderivater som phosphodiesteraseinhibitorer |
| WO2009067597A1 (en) * | 2007-11-21 | 2009-05-28 | Decode Genetics Ehf | 4- (or 5-) substituted catechol derivatives |
| JP5216912B2 (ja) * | 2008-04-29 | 2013-06-19 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｃｒ１受容体拮抗薬としてのインダゾール化合物 |
| CA2722811C (en) * | 2008-05-06 | 2016-07-05 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as ccr1 antagonists |
| KR20110060904A (ko) | 2008-09-26 | 2011-06-08 | 베링거 인겔하임 인터내셔날 게엠베하 | Ｃｃｒ1 수용체 길항제로서의 아자인다졸 화합물 |
| DK2491028T3 (da) | 2009-10-21 | 2014-01-13 | Boehringer Ingelheim Int | Indazol og pyrazolopyridine forbindelser som CCR1 receptor antagonister |
| EP2493875B1 (en) | 2009-10-27 | 2014-08-06 | Boehringer Ingelheim International GmbH | Heterocyclic compounds as ccr1 receptor antagonists |
| IN2012DN05081A (es) * | 2009-12-08 | 2015-10-09 | Boehringer Ingelheim Int | |
| AU2010334804B2 (en) * | 2009-12-23 | 2015-04-02 | Palau Pharma, S.L.U. | Aminoalkylpyrimidine derivatives as histamine H4 receptor antagonists |
| EP2563787B1 (en) | 2010-04-30 | 2014-11-26 | Boehringer Ingelheim International GmbH | Azaindazole amide compounds as ccr1 receptor antagonists |
| US8293738B2 (en) | 2010-05-12 | 2012-10-23 | Abbott Laboratories | Indazole inhibitors of kinase |
| EP2655371B1 (en) | 2010-12-23 | 2015-02-25 | Boehringer Ingelheim International GmbH | Pyrazolopiperidine compounds as ccr1 receptor antagonists |
| TW201607923A (zh) | 2014-07-15 | 2016-03-01 | 歌林達有限公司 | 被取代之氮螺環（４．５）癸烷衍生物 |
| HUE040133T2 (hu) | 2014-07-15 | 2019-02-28 | Gruenenthal Gmbh | Szubsztituált azaspiro(4.5)dekán származékok |
| WO2019147824A1 (en) | 2018-01-26 | 2019-08-01 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor |
| US20220249814A1 (en) | 2018-11-19 | 2022-08-11 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
| EP4309722A3 (en) | 2019-12-13 | 2024-08-07 | Biora Therapeutics, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| WO2021138391A1 (en) | 2019-12-30 | 2021-07-08 | Tyra Biosciences, Inc. | Indazole compounds |
| US11457370B2 (en) | 2020-12-11 | 2022-09-27 | Hewlett Packard Enterprise Development Lp | System and method for seamless live upgrade of access points using neighbor data |
| CA3205986A1 (en) | 2020-12-30 | 2022-07-07 | Tyra Biosciences, Inc. | Indazole compounds as kinase inhibitors |
| CN116003325B (zh) * | 2023-01-09 | 2025-04-25 | 南方医科大学 | 吲唑类化合物或其药学上可接受的盐及其制备方法和应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2064304A1 (de) * | 1970-12-29 | 1972-07-20 | Agfa-Gevaert Ag, 5090 Leverkusen | Lichtempfindliches farbfotografisches Material |
| KR100188801B1 (ko) * | 1990-05-18 | 1999-06-01 | 엥겔하르트 라피체 | 이속사졸-4카복스아미드 및 하이드록시알킬리덴 시아노아세트아미드 및 이들 화합물을 함유하는 약제학적 조성물 |
| US5440038A (en) * | 1993-12-07 | 1995-08-08 | Miles Inc. | Process for the purification of substituted 4-amino-1,2,4-triazine-5-ones |
| US6005118A (en) * | 1996-05-03 | 1999-12-21 | Caron; Stephane | Methods of preparing 4-cyano-4 (substituted indazole) cyclohexane-carboxylic acids useful as PDE4 inhibitors |
| AP2001002304A0 (en) * | 1996-05-03 | 2001-12-31 | Pfizer | Substituted indazole derivatives and related compounds |
| ES2201299T3 (es) * | 1996-06-25 | 2004-03-16 | Pfizer Inc. | Derivados sustituidos de indazol y su uso como inhibidores de fosfodiesterasa (pde) de tipo iv y factor de necrosis tumoral (tnf)`. |
| DE69709493T2 (de) * | 1996-06-27 | 2002-10-31 | Pfizer Inc., New York | Substituierte Indazolderivate |
| BR9712005A (pt) * | 1996-09-04 | 1999-08-24 | Pfizer | Derivados de indazol e seus usos como inibidores de fosfodiesterase (pde) tipo IV e produ-Æo do fator de necrose de tumor (tnf) |
| PT983249E (pt) * | 1997-05-08 | 2002-08-30 | Pfizer Prod Inc | Procesos e intermediarios para a preparacao de derivados de indazole substituidos |
| EA200000488A1 (ru) * | 1997-11-04 | 2000-10-30 | Пфайзер Продактс Инк. | Замена катехина на биоизостеру индазола в терапевтически активных соединениях |
-
1998
- 1998-10-09 EA EA200000385A patent/EA200000385A1/ru unknown
- 1998-10-09 WO PCT/IB1998/001579 patent/WO1999023076A1/en not_active Ceased
- 1998-10-09 CZ CZ20001623A patent/CZ20001623A3/cs unknown
- 1998-10-09 CN CN98811981A patent/CN1281441A/zh active Pending
- 1998-10-09 ID IDW20000820A patent/ID24942A/id unknown
- 1998-10-09 TR TR2000/01256T patent/TR200001256T2/xx unknown
- 1998-10-09 BR BR9813938-0A patent/BR9813938A/pt not_active Application Discontinuation
- 1998-10-09 SK SK626-2000A patent/SK6262000A3/sk unknown
- 1998-10-09 AU AU92777/98A patent/AU754184B2/en not_active Ceased
- 1998-10-09 YU YU25400A patent/YU25400A/sh unknown
- 1998-10-09 CA CA002309175A patent/CA2309175A1/en not_active Abandoned
- 1998-10-09 EP EP98945473A patent/EP1040100A1/en not_active Withdrawn
- 1998-10-09 KR KR1020007004849A patent/KR20010031783A/ko not_active Abandoned
- 1998-10-09 NZ NZ503995A patent/NZ503995A/xx unknown
- 1998-10-09 HU HU0100330A patent/HUP0100330A3/hu unknown
- 1998-10-09 PL PL98340799A patent/PL340799A1/xx not_active Application Discontinuation
- 1998-10-09 HR HR20000262A patent/HRP20000262A2/xx not_active Application Discontinuation
- 1998-10-09 JP JP2000518951A patent/JP2001521925A/ja not_active Ceased
- 1998-10-09 US US09/381,446 patent/US6716978B2/en not_active Expired - Fee Related
- 1998-10-09 IL IL13571498A patent/IL135714A0/xx unknown
- 1998-10-30 PA PA19988462601A patent/PA8462601A1/es unknown
- 1998-11-02 AP APAP/P/1998/001376A patent/AP1122A/en active
- 1998-11-03 PE PE1998001040A patent/PE131099A1/es not_active Application Discontinuation
- 1998-11-03 AR ARP980105533A patent/AR016413A1/es not_active Application Discontinuation
- 1998-11-03 ZA ZA9810042A patent/ZA9810042B/xx unknown
- 1998-11-03 TN TNTNSN98199A patent/TNSN98199A1/fr unknown
- 1998-11-03 DZ DZ980249A patent/DZ2639A1/xx active
- 1998-11-03 MA MA25331A patent/MA26562A1/fr unknown
- 1998-11-04 HN HN1998000172A patent/HN1998000172A/es unknown
- 1998-11-04 UY UY25232A patent/UY25232A1/es not_active Application Discontinuation
-
2000
- 2000-04-14 IS IS5452A patent/IS5452A/is unknown
- 2000-04-26 NO NO20002127A patent/NO20002127L/no unknown
- 2000-04-28 OA OA1200000126A patent/OA11353A/en unknown
- 2000-04-28 BG BG104391A patent/BG104391A/xx unknown
-
2002
- 2002-12-12 US US10/317,779 patent/US20030158189A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY25232A1 (es) | Compuestos terapéuticamente activos basados en el reemplazo bioisostero del catecol por el indazol en inhibidores de pde 4 . | |
| BRPI0409227B8 (pt) | "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)" | |
| TW200505903A (en) | CGRP receptor antagonists | |
| PA8575401A1 (es) | Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metrodos para su uso | |
| ATE490788T1 (de) | Antivirale phosphonate analoge | |
| GT200100196A (es) | Nuevos tiadiazoles y oxadiazoles y su uso como inhibidores de fosfodiesterasa-7. | |
| DK0672031T3 (da) | Catecholdiethere som selektive PDE IV-inhibitorer | |
| AR060749A1 (es) | Uso de bifenilamidas de acido arilcarboxilico para el tratamiento de semillas | |
| BR0312729A (pt) | Novos derivados de indol-3-enxofre | |
| BR0212617A (pt) | Compostos de pirazolila substituìdo para o tratamento de inflamação | |
| MX2023010087A (es) | Derivados heterociclicos como inhibidores de cinasas jano. | |
| PL376324A1 (en) | Piperazinyl and diazapanyl benzamides and benzthioamides | |
| ECSP045156A (es) | Derivados de indolilalquilamina como ligandos 5-hidroxitriptamina-6 | |
| DE602004015277D1 (de) | Substituierte-1-phthalazinamine als vr-1-antagonisten | |
| YU75603A (sh) | Dihidropirimidinska jedinjenja koja su supstituisana na cijano grupi i njihova upotreba u lečenju oboljenja | |
| YU75803A (sh) | Nova dihidropirimidinska jedinjenja koja su supstituisana na cijano grupi i njihova upotreba u lečenju oboljenja | |
| BRPI0407968A (pt) | derivados de oxamida úteis como inibidores de raf-quinase | |
| DE60129829D1 (de) | Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie | |
| MX2023010083A (es) | Derivados heterociclicos como inhibidores de cinasas jano. | |
| KR950702554A (ko) | 소염제로서 유용한 2-헤테로시클릭-5-히드록시-1,3-피리미딘 (2-Heterocyclic-5-Hydroxy-1,3-Pyrimidines Useful as Antiinflammatory Agents) | |
| BRPI0410657A (pt) | composto, composição farmacêutica, uso de um composto, método para tratar um distúrbio de um paciente, e, processo para a preparação de um composto | |
| CO5170464A1 (es) | Derivados de 1-trifluorometil-4-hidroxi-7-piperidinil- aminometilcromano | |
| AR002755A1 (es) | Compuestos antimicrobianos ciclohexenilo y ciclohexilo 2-disubstituidos, procedimiento para su preparacion y composiciones farmaceuticas que loscontienen. | |
| CO5261624A1 (es) | Novedosos derivados fenilheteroalquilamina, procesos para su preparacion, composiciones farmaceuticas que comprenden dichos derivados novedosos y su uso en terapia | |
| BG103395A (en) | Derivatives of benzenesulphonamide and medicaments containing them |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20101008 |